Breaking News

bluebird bio Opens Gene and Cell Therapy Mfg. Facility

NC's Gov. Cooper to cut ribbon on facility that will strengthen bluebird's capabilities to make products for clinical devt. and commercial supply

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

bluebird bio has opened its first wholly owned manufacturing facility in Durham, NC that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.   Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in a ribbon cutt...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters